In silico Screening of Violacein as an epidermal growth factor receptor inhibitor

Authors

Smitha S Bhat, Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysore
Sindhu R, Department of Microbiology, JSS Academy of Higher Education and Research, Mysore
Shashanka K Prasad, Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, MysoreFollow

Abstract

EGFR is a key player in the signalling cascades of various kinds of cancers and tyrosine kinase inhibitors block EGFR signalling. Natural products have long been used as candidates for therapy in the management of cancer. Violacein, a bacterial pigment, has been known for its numerous biological applications such as antimicrobial, antileishmanial, antiviral, as well as antitumoral. Computational studies have concluded that it may have activity against cancers like pancreatic cancer, thyroid cancer, colorectal cancer, and endometrial cancer indicating its potential application as a broad range of anti-cancerous drug. This study aimed to perform the molecular docking of violacein with the EGFR protein to ascertain its EGFR inhibitor property, which could lead to the development of a novel anti-cancer drug.

Recommended Citation

Bhat, Smitha S; R, Sindhu; and Prasad, Shashanka K (2022) "In silico Screening of Violacein as an epidermal growth factor receptor inhibitor," International Journal of Health and Allied Sciences: Vol. 11: Iss. 1, Article 6.
DOI: 10.55691/2278-344X.1007
Available at: https://rescon.jssuni.edu.in/ijhas/vol11/iss1/6